Prilocard 1.25 mg tablets for dogs

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

şimdi satın al

Indir Ürün özellikleri (SPC)
12-06-2017

Aktif bileşen:

Ramipril

Mevcut itibaren:

aniMedica GmbH

ATC kodu:

QC09AA05

INN (International Adı):

Ramipril

Doz:

1.25 mg/tablet

Farmasötik formu:

Tablet

Reçete türü:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapötik grubu:

Dogs

Terapötik alanı:

ramipril

Terapötik endikasyonlar:

Cardiovascular

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2012-07-13

Ürün özellikleri

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Prilocard 1.25 mg tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active substance:
Ramipril 1.25 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablets.
White round biconvex tablets, imprinted with ‘B’ on one side of
the tablet and ‘48’ on the other.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For treatment of congestive heart failure (equivalent to New York
Heart Association [NYHA] classes II,
III and IV)
caused by valvular
insufficiency due to endocardiosis or
cardiomyopathy.
The preparation may if
applicable be
administered concomitantly with furosemide (diuretic) and/or the
cardiac glycosides digoxin or methyl digoxin.
In patients treated concomitantly with ramipril and furosemide, the
diuretic dose may be reduced to achieve the same
diuretic effect as in treatment with furosemide alone.
4.3 CONTRAINDICATIONS
Do not
use in haemodynamically-related stenoses (e.g.
aortic stenosis,
mitral
stenosis)
nor
in cases of
obstructive
hypertrophic cardiomyopathy.
Do not use in cases of hypersensitivity to the active substance,
ACE-inhibitors or to any of the excipient(s).
See Section 4.7 for use in Pregnancy and Lactation
Class
Clinical symptoms
II
Fatigue, dyspnoea, cough etc. seen in normal activity.
Ascites may occur at this stage.
III
Comfortable at rest, but capacity for activity minimal.
IV
Incapable of any activity.
Clinical symptoms of disablement occur even at rest.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___

                                
                                Belgenin tamamını okuyun
                                
                            

Bu ürünle ilgili arama uyarıları